Howard Schecht, MD
Neurology · Toledo, OHNPI 1710984711
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $141,676 of the $183,219 with a category attached, or 77.3%. 60 manufacturers reported payments, led by Amgen at 41.3% of the total. Reporting peaked in 2019 at $74,225 and has fallen 92.9% since, to $5,244 in 2025. Among neurology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,879 payments — averaging $97.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$76K
- AbbVie$33K
- Teva Pharmaceuticals USA, Inc.$23K
- EMD Serono, Inc.$21K
- Novartis$5K
- Biogen$3K
- plus $23K from 54 others
Across 121 payments — averaging $3143.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$287K
- Roche Products Limited$27K
- Teva Pharmaceuticals USA, Inc.$21K
- Biogen$18K
- AbbVie$18K
- EMD Serono, Inc.$9K
- plus $333 from 1 others
What the payments were for
- Consulting fees$2,9252%
- Speaking & faculty fees$141,67677%
- Travel & lodging$4,0402%
- Food & beverage$34,02819%
- Education$5490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$183,219 in reported general payments places this provider in the 90th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Teriflunomide | 23 | $176,359 |
| RebifInterferon Beta-1a/Albumin | 13 | $121,673 |
| ZeposiaOzanimod Hydrochloride | 11 | $90,357 |
| CopaxoneGlatiramer Acetate | 11 | $62,843 |
| NuplazidPimavanserin Tartrate | 12 | $51,707 |
| RytaryCarbidopa/Levodopa | 19 | $39,518 |
| Glatiramer Acetate | 13 | $33,248 |
| UbrelvyUbrogepant | 30 | $28,968 |
| Emgality PenGalcanezumab-Gnlm | 38 | $25,321 |
| Nurtec OdtRimegepant Sulfate | 11 | $22,910 |
| QuliptaAtogepant | 16 | $17,179 |
| NamzaricMemantine Hcl/Donepezil Hcl | 14 | $14,869 |
| Memantine Hcl | 239 | $9,982 |
| Lacosamide | 80 | $7,359 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 35 | $7,254 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Rebif | $21,483 | $121,67313 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $1,778 | $90,35711 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $22,917 | $62,84311 claims |
| AbbVieUbrelvy, Qulipta, Namzaric | $32,860 | $61,01660 claims |
| Acadia Pharmaceuticals IncNuplazid | $1,054 | $51,70712 claims |
| Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil, Pyridostigmine Bromide | $2,572 | $43,93879 claims |
| PfizerNurtec Odt, Dilantin | $531 | $27,48226 claims |
| AstraZenecaBrilinta | $1,075 | $2,77211 claims |
| Upsher-smith Laboratories LLCTopiramate | $121 | $1,20198 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 702 neurology providers in Ohio.
Other neurology in Toledo
- Lawrence ElmerToledo$687K
- Faizan HafeezToledo$337K
- Aram ZabetiCincinnati$1.6M
- Kenneth MankowskiColumbus$1.4M
- Aaron BosterColumbus$1.2M
- Martin TaylorNew Albany$821K
- Jacqueline NicholasColumbus$743K
- Kenneth PugarCenterville$582K
- Brendan BauerSheffield Village$548K
- Geoffrey EubankColumbus$508K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.